Evidence map›Paper›PMID 26337731›Full record

ArticleCell transplantation2016

Kidney Versus Islet Allograft Survival After Induction of Mixed Chimerism With Combined Donor Bone Marrow Transplantation.

Tetsu Oura, Dicken S C Ko, Svjetlan Boskovic, John J O'Neil, Vaja Chipashvili, Maria Koulmanda, Kiyohiko Hotta, Kento Kawai, Ognjenka Nadazdin, R Neal Smith and 2 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Cell transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. β cell replacement therapy for the cure of diabetes.Journal of diabetes investigation · 2022
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Immunosuppression With CD40 Costimulatory Blockade Plus Rapamycin for Simultaneous Islet-Kidney Transplantation in Nonhuman Primates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Tetsu OuraCenter for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Dicken S C Ko
Svjetlan Boskovic
John J O'Neil
Vaja Chipashvili
Maria Koulmanda
Kiyohiko Hotta
Kento Kawai
Ognjenka Nadazdin
R Neal Smith
A B Cosimi
Tatsuo Kawai
Massachusetts General Hospital · USHarvard University · USBeth Israel Deaconess Medical Center · USJanssen (United States) · US

Funding

XENOGENIC TOLERANCE IN MICEP01HL018646 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MADSEN, JOREN C · 1985 to 2019
$37.5M
Tolerance to Composite Islet-Kidney Transplants in Non-Human PrimatesU19AI102405 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI COSIMI, A BENEDICT · 2012 to 2016
$7.7M
MIXED CHIMERISM AND TOLERANCE IN CYNOMOLGUS MONKEYSR01AI037692 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KAWAI, TATSUO · 1995 to 2005
$2.0M
NHLBI NIH HHS P01 HL018646NIAID NIH HHS R01 AI037692NIAID NIH HHS U19 AI102405
6 · The paper itself

Abstract

We have previously reported successful induction of transient mixed chimerism and long-term acceptance of renal allografts in MHC mismatched nonhuman primates. In this study, we attempted to extend this tolerance induction approach to islet allografts. A total of eight recipients underwent MHC mismatched combined islet and bone marrow (BM) transplantation after induction of diabetes by streptozotocin. Three recipients were treated after a nonmyeloablative conditioning regimen that included low-dose total body and thymic irradiation, horse Atgam (ATG), six doses of anti-CD154 monoclonal antibody (mAb), and a 1-month course of cyclosporine (CyA) (Islet A). In Islet B, anti-CD8 mAb was administered in place of CyA. In Islet C, two recipients were treated with Islet B, but without ATG. The results were compared with previously reported results of eight cynomolgus monkeys that received combined kidney and BM transplantation (Kidney A) following the same conditioning regimen used in Islet A. The majority of kidney/BM recipients achieved long-term renal allograft survival after induction of transient chimerism. However, prolonged islet survival was not achieved in similarly conditioned islet/BM recipients (Islet A), despite induction of comparable levels of chimerism. In order to rule out islet allograft loss due to CyA toxicity, three recipients were treated with anti-CD8 mAb in place of CyA. Although these recipients developed significantly superior mixed chimerism and more prolonged islet allograft survival (61, 103, and 113 days), islet function was lost soon after the disappearance of chimerism. In Islet C recipients, neither prolonged chimerism nor islet survival was observed (30 and 40 days). Significant improvement of mixed chimerism induction and islet allograft survival were achieved with a CyA-free regimen that included anti-CD8 mAb. However, unlike the kidney allograft, islet allograft tolerance was not induced with transient chimerism. Induction of more durable mixed chimerism may be necessary for induction of islet allograft tolerance.

Indexed as

Bone Marrow TransplantationChimerismIslets of Langerhans TransplantationKidney TransplantationTransplantation ChimeraAllograftsAnimalsAntibodies, MonoclonalCyclosporineCytokinesGraft SurvivalImmune ToleranceMacaca fascicularisMaleTransplantation ConditioningAntibodies, MonoclonalCyclosporineCytokines

Identifiers

PMID26337731
PMCPMC4946954
OpenAlexW2461104165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.